1454 completed, 532 recruiting, 381 terminated, 358 unknown. 1263 Phase 2, 1180 Phase 1, 447 Not applicable, 178 Phase 3, 151 Early Phase 1.
Follow this condition Literature Review of Glioma trials Research Report on Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas RNS System Implantation - Glioma, Glioma Intracranial | Not applicable | Not yet recruiting | Medical College of Wisconsin | 3 | 2028-08-01 | 2026-10-13 |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Residual IDH1-Mutant Tumor Cell Quantification Study UR-ddPCR - Glioma | Not applicable | Not yet recruiting | NYU Langone Health | 105 | 2027-08-01 | 2026-09-29 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-09-01 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors [F-18]MeFAMP PET - Healthy Volunteers, Recurrent Glioma | Early Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 28 | 2027-04-01 | 2026-08-20 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 | Phase 3 | Not yet recruiting | Nuvation Bio Inc. | 140 | 2027-03-01 | 2026-07-17 |
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
| Oral Gallium Maltolate for Recurrent Glioblastoma Gallium Maltolate, Surgical Intervention - Glioblastoma | Early Phase 1 | Not yet recruiting | Medical College of Wisconsin | 8 | 2027-03-01 | 2026-09-23 |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma | Phase 2 | Recruiting | Nuvation Bio Inc. | 40 | 2027-03-01 | 2026-10-20 |
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma Biospecimen Collection, Computed Tomography, Dexamethasone - Glioblastoma, Malignant Glioma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 24 | 2027-02-17 | 2026-08-27 |
| Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) Tovorafenib - High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV) | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 79 | 2027-02-01 | 2026-10-20 |
| Efficacy of Zoster Vaccination in Glioblastoma Patients Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination - Glioblastoma (GBM) | Phase 4 | Not yet recruiting | University Hospital, Essen | 230 | 2027-01-02 | 2026-04-23 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL) IDH1R132H-vac, Vorasidenib 40 mg Oral Tablet, Aldara - Imiquimod 5% - Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 | Phase 1 | Not yet recruiting | Heidelberg University | 45 | 2027-01-01 | 2026-10-16 |
| CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) CM93 - Glioblastoma | Phase 1 | Not yet recruiting | Crimson Biopharm Inc. | 72 | 2027-01-01 | 2024-08-21 |
Showing 20 of 3325. Sign in to see all of them.
Glioblastoma (2067) · Brain Neoplasms (871) · Astrocytoma (676) · Gliosarcoma (487) · Central Nervous System Neoplasms (420) · Oligodendroglioma (410) · Medulloblastoma (314) · Ependymoma (219) · Neoplasms (190) · Recurrence (139) · Diffuse Intrinsic Pontine Glioma (118) · Meningioma (102) · Neuroblastoma (100) · Sarcoma (93)
Neoplasms, Glandular and Epithelial (3321) · Neoplasms by Histologic Type (3314) · Neoplasms, Nerve Tissue (3314) · Neuroectodermal Tumors (3310) · Neoplasms, Neuroepithelial (3303) · Neoplasms, Germ Cell and Embryonal (3295) · Neoplasms (3135) · Astrocytoma (1617) · Neoplasms by Site (1385) · Nervous System Diseases (1279) · Nervous System Neoplasms (1238) · Central Nervous System Diseases (1055) · Brain Diseases (1043) · Central Nervous System Neoplasms (806)
Temozolomide (530) · Radiotherapy (281) · Bevacizumab (199) · Magnetic Resonance Spectroscopy (136) · Radiation (105) · Lomustine (78) · Carboplatin (76) · Irinotecan (66) · Cyclophosphamide (60) · Surgical Procedures, Operative (59) · Specimen Handling (53) · pembrolizumab (51) · Carmustine (50) · Nivolumab (50) · Etoposide (47)
National Cancer Institute (NCI) (210) · M.D. Anderson Cancer Center (70) · Duke University (69) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (68) · Memorial Sloan Kettering Cancer Center (39) · Children's Oncology Group (36) · Mayo Clinic (34) · Jonsson Comprehensive Cancer Center (32) · Novartis Pharmaceuticals (30) · Washington University School of Medicine (30) · European Organisation for Research and Treatment of Cancer - EORTC (28) · Case Comprehensive Cancer Center (27) · Pediatric Brain Tumor Consortium (26) · University of Florida (26) · City of Hope Medical Center (25)
United States (1981) · China (288) · France (267) · Canada (238) · Germany (184) · United Kingdom (150) · Netherlands (149) · Italy (148) · Spain (135) · Australia (127) · Switzerland (126) · Belgium (83) · Austria (60) · Denmark (57) · South Korea (50)
Annick Desjardins, MD, FRCPC (16) · Nader Sanai, MD (16) · David A. Reardon, MD (15) · Henry S. Friedman, MD (14) · Stanislaw R. Burzynski, MD, PhD (14) · David Peereboom, MD (12) · John Boockvar, MD (12) · Stuart A. Grossman, MD (12) · Maryam Fouladi, MD (11) · Annick Desjardins, MD (9) · Katherine B Peters, MD, PhD (9)
PMID 31401903, PMID 34171339, PMID 38335473, PMID 19269895, PMID 32691060, PMID 36346112, PMID 38968568, PMID 39777725, PMID 15758009, PMID 23545055, PMID 24552317, PMID 25098701, PMID 25113840, PMID 29023494, PMID 29982805, PMID 34081125, PMID 35468680, PMID 37142373, PMID 37540556, PMID 12749708, PMID 16200343, PMID 16520474, PMID 17705175, PMID 20694800, PMID 21865400, PMID 23243055, PMID 23377664, PMID 23817721, PMID 23940216, PMID 24101040, PMID 24309981, PMID 24327518, PMID 24344045, PMID 24552318, PMID 24893855, PMID 26169613, PMID 27424289, PMID 27580889, PMID 27744512, PMID 28039367, PMID 28053024, PMID 28672195, PMID 29077941, PMID 29383130, PMID 29412784, PMID 29846250, PMID 30053159, PMID 30118397, PMID 31101621, PMID 31386061
U10CA180886 (27), U01CA062475 (23), U01CA081457 (23), 2023 (18), P30CA033572 (18), U10CA098543 (18), UM1CA081457 (18), 2009 (13), 2018 (13), UM1CA137443 (13), U10CA025224 (12), U01CA062399 (11), U01CA137443 (11), U10CA180868 (11), 2014 (10)